Redsense Medical (REDS) Q1 2026 earnings summary

Executive summary

• Net sales grew 34% year-over-year to KSEK 6,402, driven by increased adoption and broader customer mix, especially in the U.S. market.

• Operating profit (EBIT) reached KSEK 1,077, a turnaround from a loss of KSEK -3,152 in Q1 2025.

• Gross margin improved to 76%, reflecting higher disposable sales and operational efficiency.

• Cash position at quarter-end was KSEK 9,738, with an unused credit facility of KSEK 1,000.

• First commercial sale of the Clamp System in the UK and positive pilot results in Germany signal international expansion.

Financial highlights

• Net sales: KSEK 6,402 (up from 4,776 year-over-year).

• EBIT: KSEK 1,077 (up from -3,152 year-over-year).

• Earnings per share: SEK 0.07 (up from -0.19 year-over-year).

• Gross profit: KSEK 4,879 (up from 2,219 year-over-year).

• Cash flow from operating activities: KSEK 2,760 (up from 761 year-over-year).

Outlook and guidance

• Focus remains on disciplined execution, increasing U.S. end-customer usage, progressing Clamp rollout, and expanding into new markets.

• Operational improvements and revised U.S. pricing structure expected to support continued growth and broader adoption.